APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liposome Drug Delivery

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Selected research

Market Structure

Global Liposome Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

9 January 2026196 pages

Choose your research edition.

Industry ResearchLiposome Drug Delivery Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposome Drug Delivery Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Liposome Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposome Drug Delivery Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposome Drug Delivery Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only. In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.

Global Liposome Drug Delivery key players include Gilead Sciences, Pacira, Sun Pharmaceutical, Johnson & Johnson, Luye Pharma, etc. Global top five manufacturers hold a share about 60%. North America is the largest market, with a share about 40%, followed by Europe and Asia-Pacific, both with a share about 30 percent. In terms of product, Liposomal Doxorubicin is the largest segment, with a share about 40%. And in terms of application, the largest application is Cancer & Tumor Therapy, followed by Fungal Infection Therapy, etc.

This report provides an overview of the global Liposome Drug Delivery market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Liposome Drug Delivery and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liposome Drug Delivery sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liposome Drug Delivery market size, projected growth trends, production technologies, key applications, and end-use industries.

Liposome Drug Delivery Segment by Company

Gilead Sciences

Pacira

Sun Pharmaceutical

Johnson & Johnson

Luye Pharma

Sigma-Tau

Ipsen (Onivyde)

CSPC

Teva Pharmaceutical

Novartis

Fudan-Zhangjiang

Liposome Drug Delivery Segment by Type

Liposomal Doxorubicin

Liposomal Amphoteracin B

Liposomal Paclitaxel

Others

Liposome Drug Delivery Segment by Application

Fungal Infection Therapy

Cancer & Tumor Therapy

Others

Liposome Drug Delivery Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposome Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposome Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposome Drug Delivery.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liposome Drug Delivery market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Liposome Drug Delivery manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Liposome Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Liposome Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Liposome Drug Delivery Industry Trends Table 2. Liposome Drug Delivery Industry Drivers Table 3. Liposome Drug Delivery Industry Opportunities and Challenges Table 4. Liposome Drug Delivery Industry Restraints Table 5. Global Liposome Drug Delivery Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Liposome Drug Delivery Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Liposome Drug Delivery Sales by Manufacturers (K Vial) & (2021-2026) Table 8. Global Liposome Drug Delivery Sales Market Share by Manufacturers Table 9. Global Liposome Drug Delivery Average Sales Price (USD/Vial) of Manufacturers (2021-2026) Table 10. Global Liposome Drug Delivery Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Liposome Drug Delivery Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Liposome Drug Delivery Manufacturers, Product Type & Application Table 13. Global Liposome Drug Delivery Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Liposome Drug Delivery by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Liposomal Doxorubicin Table 17. Major Manufacturers of Liposomal Amphoteracin B Table 18. Major Manufacturers of Liposomal Paclitaxel Table 19. Major Manufacturers of Others Table 20. Global Liposome Drug Delivery Sales by Type 2021 VS 2025 VS 2032 (K Vial) Table 21. Global Liposome Drug Delivery Sales by Type (2021-2026) & (K Vial) Table 22. Global Liposome Drug Delivery Sales by Type (2027-2032) & (K Vial) Table 23. Global Liposome Drug Delivery Sales Market Share by Type (2021-2026) Table 24. Global Liposome Drug Delivery Sales Market Share by Type (2027-2032) Table 25. Global Liposome Drug Delivery Revenue by Type 2021 VS 2025 VS 2032 (K Vial) Table 26. Global Liposome Drug Delivery Revenue by Type (2021-2026) & (K Vial) Table 27. Global Liposome Drug Delivery Revenue by Type (2027-2032) & (K Vial) Table 28. Global Liposome Drug Delivery Revenue Market Share by Type (2021-2026) Table 29. Global Liposome Drug Delivery Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Fungal Infection Therapy Table 31. Major Manufacturers of Cancer & Tumor Therapy Table 32. Major Manufacturers of Others Table 33. Global Liposome Drug Delivery Sales by Application 2021 VS 2025 VS 2032 (K Vial) Table 34. Global Liposome Drug Delivery Sales by Application (2021-2026) & (K Vial) Table 35. Global Liposome Drug Delivery Sales by Application (2027-2032) & (K Vial) Table 36. Global Liposome Drug Delivery Sales Market Share by Application (2021-2026) Table 37. Global Liposome Drug Delivery Sales Market Share by Application (2027-2032) Table 38. Global Liposome Drug Delivery Revenue by Application 2021 VS 2025 VS 2032 (K Vial) Table 39. Global Liposome Drug Delivery Revenue by Application (2021-2026) & (K Vial) Table 40. Global Liposome Drug Delivery Revenue by Application (2027-2032) & (K Vial) Table 41. Global Liposome Drug Delivery Revenue Market Share by Application (2021-2026) Table 42. Global Liposome Drug Delivery Revenue Market Share by Application (2027-2032) Table 43. Global Liposome Drug Delivery Sales by Region: 2021 VS 2025 VS 2032 (K Vial) Table 44. Global Liposome Drug Delivery Sales by Region (2021-2026) & (K Vial) Table 45. Global Liposome Drug Delivery Sales Market Share by Region (2021-2026) Table 46. Global Liposome Drug Delivery Sales Forecasted by Region (2027-2032) & (K Vial) Table 47. Global Liposome Drug Delivery Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Vial) Table 49. North America Liposome Drug Delivery Sales by Country (2021-2026) & (K Vial) Table 50. North America Liposome Drug Delivery Sales by Country (2027-2032) & (K Vial) Table 51. Europe Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Vial) Table 52. Europe Liposome Drug Delivery Sales by Country (2021-2026) & (K Vial) Table 53. Europe Liposome Drug Delivery Sales by Country (2027-2032) & (K Vial) Table 54. Asia Pacific Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Vial) Table 55. Asia Pacific Liposome Drug Delivery Sales by Country (2021-2026) & (K Vial) Table 56. Asia Pacific Liposome Drug Delivery Sales by Country (2027-2032) & (K Vial) Table 57. South America, Middle East and Africa Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Vial) Table 58. South America, Middle East and Africa Liposome Drug Delivery Sales by Country (2021-2026) & (K Vial) Table 59. South America, Middle East and Africa Liposome Drug Delivery Sales by Country (2027-2032) & (K Vial) Table 60. Global Liposome Drug Delivery Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Liposome Drug Delivery Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Liposome Drug Delivery Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Liposome Drug Delivery Revenue Market Share by Region (2021-2026) Table 64. Global Liposome Drug Delivery Revenue Market Share by Region (2027-2032) Table 65. Gilead Sciences Company Information Table 66. Gilead Sciences Business Overview Table 67. Gilead Sciences Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Gilead Sciences Liposome Drug Delivery Product Portfolio Table 69. Gilead Sciences Recent Development Table 70. Pacira Company Information Table 71. Pacira Business Overview Table 72. Pacira Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Pacira Liposome Drug Delivery Product Portfolio Table 74. Pacira Recent Development Table 75. Sun Pharmaceutical Company Information Table 76. Sun Pharmaceutical Business Overview Table 77. Sun Pharmaceutical Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sun Pharmaceutical Liposome Drug Delivery Product Portfolio Table 79. Sun Pharmaceutical Recent Development Table 80. Johnson & Johnson Company Information Table 81. Johnson & Johnson Business Overview Table 82. Johnson & Johnson Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Johnson & Johnson Liposome Drug Delivery Product Portfolio Table 84. Johnson & Johnson Recent Development Table 85. Luye Pharma Company Information Table 86. Luye Pharma Business Overview Table 87. Luye Pharma Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Luye Pharma Liposome Drug Delivery Product Portfolio Table 89. Luye Pharma Recent Development Table 90. Sigma-Tau Company Information Table 91. Sigma-Tau Business Overview Table 92. Sigma-Tau Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Sigma-Tau Liposome Drug Delivery Product Portfolio Table 94. Sigma-Tau Recent Development Table 95. Ipsen (Onivyde) Company Information Table 96. Ipsen (Onivyde) Business Overview Table 97. Ipsen (Onivyde) Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Ipsen (Onivyde) Liposome Drug Delivery Product Portfolio Table 99. Ipsen (Onivyde) Recent Development Table 100. CSPC Company Information Table 101. CSPC Business Overview Table 102. CSPC Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. CSPC Liposome Drug Delivery Product Portfolio Table 104. CSPC Recent Development Table 105. Teva Pharmaceutical Company Information Table 106. Teva Pharmaceutical Business Overview Table 107. Teva Pharmaceutical Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Teva Pharmaceutical Liposome Drug Delivery Product Portfolio Table 109. Teva Pharmaceutical Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Novartis Liposome Drug Delivery Product Portfolio Table 114. Novartis Recent Development Table 115. Fudan-Zhangjiang Company Information Table 116. Fudan-Zhangjiang Business Overview Table 117. Fudan-Zhangjiang Liposome Drug Delivery Sales (K Vial), Price (USD/Vial), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Fudan-Zhangjiang Liposome Drug Delivery Product Portfolio Table 119. Fudan-Zhangjiang Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Liposome Drug Delivery Distributors List Table 123. Liposome Drug Delivery Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Liposome Drug Delivery Product Image Figure 2. Global Liposome Drug Delivery Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposome Drug Delivery Market Size (2021-2032) & (US$ Million) Figure 4. Global Liposome Drug Delivery Sales (2021-2032) & (K Vial) Figure 5. Global Liposome Drug Delivery Average Price (USD/Vial) & (2021-2032) Figure 6. Global Top 5 and 10 Liposome Drug Delivery Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Liposomal Doxorubicin Image Figure 9. Liposomal Amphoteracin B Image Figure 10. Liposomal Paclitaxel Image Figure 11. Others Image Figure 12. Global Liposome Drug Delivery Sales by Type (2021 VS 2025 VS 2032) & (K Vial) Figure 13. Global Liposome Drug Delivery Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Liposome Drug Delivery Sales Market Share by Type (2021-2032) Figure 15. Global Liposome Drug Delivery Revenue by Type (2021 VS 2025 VS 2032) & (K Vial) Figure 16. Global Liposome Drug Delivery Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Liposome Drug Delivery Revenue Market Share by Type (2021-2032) Figure 18. Fungal Infection Therapy Image Figure 19. Cancer & Tumor Therapy Image Figure 20. Others Image Figure 21. Global Liposome Drug Delivery Sales by Application (2021 VS 2025 VS 2032) & (K Vial) Figure 22. Global Liposome Drug Delivery Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Liposome Drug Delivery Sales Market Share by Application (2021-2032) Figure 24. Global Liposome Drug Delivery Revenue by Application (2021 VS 2025 VS 2032) & (K Vial) Figure 25. Global Liposome Drug Delivery Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Liposome Drug Delivery Revenue Market Share by Application (2021-2032) Figure 27. North America Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 28. North America Liposome Drug Delivery Sales Market Share by Country (2021-2032) Figure 29. U.S. Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 30. Canada Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 31. Mexico Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 32. Europe Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 33. Europe Liposome Drug Delivery Sales Market Share by Country (2021-2032) Figure 34. Germany Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 35. France Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 36. U.K. Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 37. Italy Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 38. Netherlands Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 39. Asia Pacific Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 40. Asia Pacific Liposome Drug Delivery Sales Market Share by Country (2021-2032) Figure 41. China Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 42. Japan Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 43. South Korea Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 44. Southeast Asia Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 45. India Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 46. Australia Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 47. South America, Middle East and Africa Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 48. South America, Middle East and Africa Liposome Drug Delivery Sales Market Share by Country (2021-2032) Figure 49. Brazil Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 50. South Africa Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 51. Saudi Arabia Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 52. Turkey Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 53. Argentina Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 54. UAE Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 55. Egypt Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 56. Chile Liposome Drug Delivery Sales and Growth Rate (2021-2032) & (K Vial) Figure 57. Global Liposome Drug Delivery Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Liposome Drug Delivery Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Liposome Drug Delivery Revenue (2021-2032) & (US$ Million) Figure 60. North America Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Liposome Drug Delivery Revenue (2021-2032) & (US$ Million) Figure 62. Europe Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Liposome Drug Delivery Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Liposome Drug Delivery Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Liposome Drug Delivery Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Liposome Drug Delivery Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomal Doxorubicin
  • Liposomal Amphoteracin B
  • Liposomal Paclitaxel
  • Others
Applications
  • Fungal Infection Therapy
  • Cancer & Tumor Therapy
  • Others
Companies covered
  • Gilead Sciences
  • Pacira
  • Sun Pharmaceutical
  • Johnson & Johnson
  • Luye Pharma
  • Sigma-Tau
  • Ipsen (Onivyde)
  • CSPC
  • Teva Pharmaceutical
  • Novartis
  • Fudan-Zhangjiang

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Liposome Drug Delivery Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Liposome Drug Delivery Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Liposome Drug Delivery Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Liposome Drug Delivery Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Liposome Drug Delivery Market Dynamics
  1. 2.1 Liposome Drug Delivery Industry Trends
  2. 2.2 Liposome Drug Delivery Industry Drivers
  3. 2.3 Liposome Drug Delivery Industry Opportunities and Challenges
  4. 2.4 Liposome Drug Delivery Industry Restraints
3 Liposome Drug Delivery Market by Manufacturers
  1. 3.1 Global Liposome Drug Delivery Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Liposome Drug Delivery Sales by Manufacturers (2021-2026)
  3. 3.3 Global Liposome Drug Delivery Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Liposome Drug Delivery Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Liposome Drug Delivery Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Liposome Drug Delivery Manufacturers, Product Type & Application
  7. 3.7 Global Liposome Drug Delivery Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Liposome Drug Delivery Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Liposome Drug Delivery Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Liposome Drug Delivery Tier 1, Tier 2, and Tier 3
4 Liposome Drug Delivery Market by Type
  1. 4.1 Liposome Drug Delivery Type Introduction
  2. 4.1.1 Liposomal Doxorubicin
  3. 4.1.2 Liposomal Amphoteracin B
  4. 4.1.3 Liposomal Paclitaxel
  5. 4.1.4 Others
  6. 4.2 Global Liposome Drug Delivery Sales by Type
  7. 4.2.1 Global Liposome Drug Delivery Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Liposome Drug Delivery Sales by Type (2021-2032)
  9. 4.2.3 Global Liposome Drug Delivery Sales Market Share by Type (2021-2032)
  10. 4.3 Global Liposome Drug Delivery Revenue by Type
  11. 4.3.1 Global Liposome Drug Delivery Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Liposome Drug Delivery Revenue by Type (2021-2032)
  13. 4.3.3 Global Liposome Drug Delivery Revenue Market Share by Type (2021-2032)
5 Liposome Drug Delivery Market by Application
  1. 5.1 Liposome Drug Delivery Application Introduction
  2. 5.1.1 Fungal Infection Therapy
  3. 5.1.2 Cancer & Tumor Therapy
  4. 5.1.3 Others
  5. 5.2 Global Liposome Drug Delivery Sales by Application
  6. 5.2.1 Global Liposome Drug Delivery Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liposome Drug Delivery Sales by Application (2021-2032)
  8. 5.2.3 Global Liposome Drug Delivery Sales Market Share by Application (2021-2032)
  9. 5.3 Global Liposome Drug Delivery Revenue by Application
  10. 5.3.1 Global Liposome Drug Delivery Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liposome Drug Delivery Revenue by Application (2021-2032)
  12. 5.3.3 Global Liposome Drug Delivery Revenue Market Share by Application (2021-2032)
6 Global Liposome Drug Delivery Sales by Region
  1. 6.1 Global Liposome Drug Delivery Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liposome Drug Delivery Sales by Region (2021-2032)
  3. 6.2.1 Global Liposome Drug Delivery Sales by Region (2021-2026)
  4. 6.2.2 Global Liposome Drug Delivery Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Liposome Drug Delivery Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Liposome Drug Delivery Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Liposome Drug Delivery Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Liposome Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Liposome Drug Delivery Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Liposome Drug Delivery Revenue by Region
  1. 7.1 Global Liposome Drug Delivery Revenue by Region
  2. 7.1.1 Global Liposome Drug Delivery Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Liposome Drug Delivery Revenue by Region (2021-2026)
  4. 7.1.3 Global Liposome Drug Delivery Revenue by Region (2027-2032)
  5. 7.1.4 Global Liposome Drug Delivery Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Liposome Drug Delivery Revenue (2021-2032)
  8. 7.2.2 North America Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Liposome Drug Delivery Revenue (2021-2032)
  11. 7.3.2 Europe Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Liposome Drug Delivery Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Liposome Drug Delivery Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Liposome Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Gilead Sciences
  2. 8.1.1 Gilead Sciences Company Information
  3. 8.1.2 Gilead Sciences Business Overview
  4. 8.1.3 Gilead Sciences Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Gilead Sciences Liposome Drug Delivery Product Portfolio
  6. 8.1.5 Gilead Sciences Recent Developments
  7. 8.2 Pacira
  8. 8.2.1 Pacira Company Information
  9. 8.2.2 Pacira Business Overview
  10. 8.2.3 Pacira Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pacira Liposome Drug Delivery Product Portfolio
  12. 8.2.5 Pacira Recent Developments
  13. 8.3 Sun Pharmaceutical
  14. 8.3.1 Sun Pharmaceutical Company Information
  15. 8.3.2 Sun Pharmaceutical Business Overview
  16. 8.3.3 Sun Pharmaceutical Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Liposome Drug Delivery Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Liposome Drug Delivery Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Luye Pharma
  26. 8.5.1 Luye Pharma Company Information
  27. 8.5.2 Luye Pharma Business Overview
  28. 8.5.3 Luye Pharma Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Luye Pharma Liposome Drug Delivery Product Portfolio
  30. 8.5.5 Luye Pharma Recent Developments
  31. 8.6 Sigma-Tau
  32. 8.6.1 Sigma-Tau Company Information
  33. 8.6.2 Sigma-Tau Business Overview
  34. 8.6.3 Sigma-Tau Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sigma-Tau Liposome Drug Delivery Product Portfolio
  36. 8.6.5 Sigma-Tau Recent Developments
  37. 8.7 Ipsen (Onivyde)
  38. 8.7.1 Ipsen (Onivyde) Company Information
  39. 8.7.2 Ipsen (Onivyde) Business Overview
  40. 8.7.3 Ipsen (Onivyde) Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Ipsen (Onivyde) Liposome Drug Delivery Product Portfolio
  42. 8.7.5 Ipsen (Onivyde) Recent Developments
  43. 8.8 CSPC
  44. 8.8.1 CSPC Company Information
  45. 8.8.2 CSPC Business Overview
  46. 8.8.3 CSPC Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CSPC Liposome Drug Delivery Product Portfolio
  48. 8.8.5 CSPC Recent Developments
  49. 8.9 Teva Pharmaceutical
  50. 8.9.1 Teva Pharmaceutical Company Information
  51. 8.9.2 Teva Pharmaceutical Business Overview
  52. 8.9.3 Teva Pharmaceutical Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Teva Pharmaceutical Liposome Drug Delivery Product Portfolio
  54. 8.9.5 Teva Pharmaceutical Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Liposome Drug Delivery Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Fudan-Zhangjiang
  62. 8.11.1 Fudan-Zhangjiang Company Information
  63. 8.11.2 Fudan-Zhangjiang Business Overview
  64. 8.11.3 Fudan-Zhangjiang Liposome Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Fudan-Zhangjiang Liposome Drug Delivery Product Portfolio
  66. 8.11.5 Fudan-Zhangjiang Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liposome Drug Delivery Value Chain Analysis
  2. 9.1.1 Liposome Drug Delivery Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liposome Drug Delivery Production Mode & Process
  6. 9.2 Liposome Drug Delivery Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liposome Drug Delivery Distributors
  9. 9.2.3 Liposome Drug Delivery Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst